title: Trichomegaly Induced by Cetuximab: Case Series and Review the Literature.
abstract: Trichomegaly is a rare side effect of epidermal growth factor receptor inhibitors. We present here 4 patients who treated with cetuximab (an epidermal growth factor receptor inhibitor) for metastatic colorectal cancer. All of the cases were treated with cetuximab 500 mg/m biweekly in combination protocol. The mean period from the start of the treatment until the development the trichomegaly was 4.75 (3-6) months. In all of the patients after the end of the cetuximab therapy, trichomegaly was regressed. Only 1 case resolved with topical treatment that conjunctivitis with trichomegaly. Trichomegaly is an important ocular toxicity of cetuximab that can cause visual discomfort and corneal damages. However, these side effects usually do not require discontinuation of treatment.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Bilim University, Istanbul, Turkey.
authors.forename: Ulkuhan I
authors.initials: UI
authors.lastname: Koksal
authors.forename: Kezban N
authors.initials: KN
authors.lastname: Pilanci
authors.forename: Cetin
authors.initials: C
authors.lastname: Ordu
authors.forename: Kerem
authors.initials: K
authors.lastname: Okutur
authors.forename: Sezer
authors.initials: S
authors.lastname: Saglam
authors.forename: Gokhan
authors.initials: G
authors.lastname: Demir
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab / Q000008:administration & dosage / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005140:Eyelashes / Q000187:drug effects* / Q000254:growth & development; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000068818:Cetuximab